A composition and its use in the manufacture of a product for maintaining blood lipid health levels

Abstract

The application provides a composition and application of the composition in preparation of a product for maintaining blood lipid health level, the composition comprises 0.1-10 parts by weight of pentadecanoic acid, further comprises 1 part by weight of ginseng and / or 0.1-5 parts by weight of hawthorn, the composition is target-specific, components are mutually matched and synergistic, has the efficacy of maintaining blood lipid health level, realizes simultaneous effective intervention on two key indexes of total cholesterol and triglyceride; the composition has a clear mechanism, obvious synergistic effect, and outstanding advantages in safety, controllability of cost and feasibility of productization, and provides important material foundation and technical support for development of an efficient, balanced and easily popularized blood lipid health management scheme.

Description

Technical Field

[0001] This invention belongs to the field of food or health food technology, and relates to a composition and its application in the preparation of products that maintain healthy blood lipid levels. Background Technology

[0002] Dyslipidemia is a core risk factor for the occurrence and development of cardiovascular disease, and its prevalence is becoming increasingly serious. Clinically, hyperlipidemia is mainly classified into hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia (comprising both) based on the type of lipid elevation. Numerous studies have confirmed that dietary intervention is a key non-pharmacological approach to regulating blood lipids and maintaining cardiovascular health. Currently, products or programs on the market with lipid-lowering functions mainly rely on single active ingredients (such as specific plant extracts or synthetic compounds). These programs suffer from limited efficacy targets and single mechanisms of action, making it difficult to comprehensively regulate the multiple metabolic processes of dyslipidemia, resulting in limited overall intervention effects. Traditional Chinese medicines such as hawthorn and cassia seed, derived from traditional Chinese medicine theory and dietary therapy practices, have been proven to have certain lipid-lowering effects, but they usually have the disadvantages of relatively large effective doses and limited intensity of single component effects. Simply increasing the dosage to achieve significant effects may lead to decreased product palatability, increased costs, or unnecessary dietary burden. On the other hand, studies on dairy nutrients (such as whey protein, conjugated linoleic acid, and milk minerals) have shown that they can assist lipid metabolism through promoting fatty acid oxidation and regulating gut microbiota. However, when used alone, its comprehensive regulatory capacity on serum total cholesterol (TC) and triglyceride (TG) levels is insufficient, making it difficult to achieve the ideal broad-spectrum lipid-lowering effect.

[0003] In summary, current technologies have not yet effectively solved the technical problem of lowering blood lipids through multi-pathway and multi-target synergy. In particular, there is a lack of compound formulations that scientifically combine traditional Chinese medicine components with milk-derived functional factors discovered by modern nutrition science to utilize their complementary or synergistic effects. This technological gap results in unsatisfactory comprehensive intervention effects of existing products, making it difficult to effectively regulate the two key blood lipid indicators of total cholesterol and triglycerides while simultaneously optimizing the cost, safety, and practicality of the formulation.

[0004] Therefore, there is an urgent need to develop a combination of traditional Chinese medicine components and milk-derived nutrients to effectively maintain healthy blood lipid levels. Summary of the Invention

[0005] To address the aforementioned technical problems, the present invention aims to provide a composition and its application in the preparation of products for maintaining healthy blood lipid levels. This composition has a clearly defined target, and the components work together synergistically to maintain healthy blood lipid levels.

[0006] To achieve the above objectives, in one respect, the present invention provides a composition comprising 0.1-10 parts by weight of pentadecanoic acid, and further comprising 1 part by weight of ginseng and / or 0.1-5 parts by weight of hawthorn.

[0007] According to a specific embodiment of the present invention, preferably, the composition comprises 0.1-5.5 parts by weight of pentadecanoic acid, and further comprises 1 part by weight of ginseng and / or 0.5-5 parts by weight of hawthorn.

[0008] According to a specific embodiment of the present invention, preferably, the composition comprises 0.1-5.5 parts by weight of pentadecanoic acid, and further comprises 1 part by weight of ginseng and / or 0.5-1 parts by weight of hawthorn.

[0009] According to a specific embodiment of the present invention, preferably, the composition includes 0.1-10 parts by weight of pentadecanoic acid and 1 part by weight of ginseng, that is, the mass ratio of ginseng to pentadecanoic acid is 1:0.1-10.

[0010] According to a specific embodiment of the present invention, preferably, the composition includes 0.1-5.5 parts by weight of pentadecanoic acid and 1 part by weight of ginseng, that is, the mass ratio of ginseng to pentadecanoic acid is 1:0.1-5.5.

[0011] According to a specific embodiment of the present invention, preferably, the composition includes 5.5 parts by weight of pentadecanoic acid and 1 part by weight of ginseng, that is, the mass ratio of ginseng to pentadecanoic acid is 1:5.5.

[0012] According to a specific embodiment of the present invention, preferably, the composition includes 0.1-10 parts by weight of pentadecanoic acid and 0.1-5 parts by weight of hawthorn, that is, the mass ratio of hawthorn to pentadecanoic acid is 0.1-5:0.1-10.

[0013] According to a specific embodiment of the present invention, preferably, the composition includes 0.1-5.5 parts by weight of pentadecanoic acid and 0.5-5 parts by weight of hawthorn, that is, the mass ratio of hawthorn to pentadecanoic acid is 0.5-5:0.1-5.5.

[0014] According to a specific embodiment of the present invention, preferably, the composition includes 0.1-5.5 parts by weight of pentadecanoic acid and 0.5-1 parts by weight of hawthorn, that is, the mass ratio of hawthorn to pentadecanoic acid is 0.5-1:0.1-5.5.

[0015] According to a specific embodiment of the present invention, preferably, the composition includes 5.5 parts by weight of pentadecanoic acid and 1 part by weight of hawthorn, that is, the mass ratio of hawthorn to pentadecanoic acid is 1:5.5.

[0016] According to a specific embodiment of the present invention, preferably, the composition comprises 1 part by weight of ginseng, 0.1-5 parts by weight of hawthorn, and 0.1-10 parts by weight of pentadecanoic acid, that is, the mass ratio of ginseng, hawthorn and pentadecanoic acid is 1:0.1-5:0.1-10.

[0017] According to a specific embodiment of the present invention, preferably, the composition comprises 1 part by weight of ginseng, 0.5-5 parts by weight of hawthorn, and 0.1-5.5 parts by weight of pentadecanoic acid, that is, the mass ratio of ginseng, hawthorn and pentadecanoic acid is 1:0.5-5:0.1-5.5.

[0018] According to a specific embodiment of the present invention, preferably, the composition comprises 1 part by weight of ginseng, 0.5-1 part by weight of hawthorn, and 0.1-5.5 parts by weight of pentadecanoic acid, that is, the mass ratio of ginseng, hawthorn and pentadecanoic acid is 1:0.5-1:0.1-5.5.

[0019] According to a specific embodiment of the present invention, preferably, the composition comprises 1 part by weight of ginseng, 1 part by weight of hawthorn, and 5.5 parts by weight of pentadecanoic acid, that is, the mass ratio of ginseng, hawthorn and pentadecanoic acid is 1:1:5.5.

[0020] According to a specific embodiment of the present invention, preferably, in the composition: the ginsenoside content of the ginseng is Rg1+Re≥0.9% and Rb1≥0.6%.

[0021] According to a specific embodiment of the present invention, preferably, the citric acid content of the hawthorn in the composition is ≥2.5%.

[0022] The ginseng mentioned in this invention is preferably ginseng powder, which is prepared by water extraction, wherein the mass ratio of ginseng to water is 1:(3-8), more preferably 1:5.

[0023] The hawthorn in this invention is preferably hawthorn powder, which is prepared by water extraction, wherein the mass ratio of hawthorn to water is 1:(13-20), more preferably 1:16.7.

[0024] On the other hand, the present invention provides a food product containing the above-described composition.

[0025] According to a specific embodiment of the present invention, preferably, the food is a nutritional product, a health food, or a food for special medical purposes.

[0026] According to a specific embodiment of the present invention, preferably, the food is adult formulated milk powder.

[0027] On the other hand, the present invention provides the use of the above-described composition or the above-described food in the preparation of products that help maintain healthy blood lipid levels.

[0028] According to a specific embodiment of the present invention, preferably, the blood lipids include cholesterol and / or triglycerides.

[0029] In some specific implementations, preferably, the method of helping to maintain healthy blood lipid levels is specifically manifested in reducing the fluorescence intensity of cholesterol in the blood vessels of zebrafish tails and reducing the staining intensity of triglycerides in the blood vessels of zebrafish tails.

[0030] According to a specific embodiment of the present invention, preferably, the product is a pharmaceutical or health food.

[0031] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0032] This invention provides a composition and its application in the preparation of products for maintaining healthy blood lipid levels. This composition creatively combines traditional Chinese medicine components (ginseng and hawthorn) with a milk-derived functional factor (pentadecanoic acid) discovered by modern nutrition science, filling a technological gap in the synergistic regulation of blood lipids through multiple pathways and targets. Its core beneficial effects are: First, through the complementarity and synergy between the components, it achieves simultaneous and effective intervention on two key indicators: total cholesterol and triglycerides. Its comprehensive efficacy is significantly superior to any single component or combination of two components; for example, a specific ratio showed superior cholesterol-lowering and triglyceride-lowering effects in a zebrafish model. Second, this formula combines theoretical innovation with practical value, integrating traditional wisdom with modern science. It not only has a clear mechanism and significant synergistic effects, but also boasts outstanding advantages in safety, cost control, and product feasibility, providing an important material basis and technical support for developing efficient, balanced, and easily promoted blood lipid health management programs. Attached Figure Description

[0033] Figure 1 Statistical analysis of cholesterol fluorescence intensity in the blood vessels of zebrafish tails after sample processing.

[0034] Figure 2 Statistical analysis of triglyceride staining intensity in zebrafish tail vessels after sample processing. Detailed Implementation

[0035] In order to provide a clearer understanding of the technical features, objectives and beneficial effects of the present invention, the technical solution of the present invention will now be described in detail below, but it should not be construed as limiting the scope of implementation of the present invention.

[0036] It should be noted that, unless otherwise specified, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0037] Unless otherwise specified, all raw materials, reagents, instruments and equipment used in this invention can be purchased from the market or prepared by existing methods.

[0038] It should be understood that the terms “comprising,” “including,” and / or “containing” as used herein specify the presence of the stated features, integers, steps, components, or combinations thereof, but do not exclude the presence or addition of one or more other features, integers, steps, components, or combinations thereof.

[0039] The endpoints and any values ​​of the ranges disclosed in this invention are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this invention.

[0040] The ginseng powder used in the following examples was obtained by water extraction of ginseng. The ginseng powder contained 0.9% ginsenoside Rg1+Re and 0.6% ginsenoside Rb1.

[0041] The hawthorn powder used in the following examples was obtained by water extraction of hawthorn, and the citric acid content in the hawthorn powder was 2.5%.

[0042] Example 1: Evaluation of Cholesterol-Lowering Efficacy

[0043] 1. Experiment Content

[0044] Five dpf wild-type AB strain zebrafish were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Water-soluble samples were administered (sample formulations and concentrations for each group are shown in Table 1). Atorvastatin calcium was used as a positive control at a concentration of 11.6 μg / mL. A normal control group and a model control group were also set up. Each beaker had a volume of 25 mL. Except for the normal control group, all other experimental groups were given a high-fat diet to establish a high-fat zebrafish model. After treatment at 28℃ for one day, a cholesterol probe was injected. After another day of treatment, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The cholesterol fluorescence intensity (B) of the zebrafish tail vessels was analyzed, and the cholesterol-lowering efficacy of the samples was evaluated using statistical analysis of this index. Statistical results are expressed as mean ± SE.

[0045] 2. Experimental Results

[0046] As shown in Table 1, Figure 1 As shown in Table 1, compared with the model control group, p < 0.05, p < 0.01, p < 0.001; Figure 1 Compared with the model control group, p < 0.05, p < 0.001, compared with ginseng powder; &&&p < 0.001, compared with hawthorn powder. p < 0.001, compared with pentadecanoic acid, p < 0.001, compared with ginseng powder: pentadecanoic acid (1:5.5), p < 0.05, compared with hawthorn powder: pentadecanoic acid (1:5.5), p < 0.01.

[0047] Analysis of the above results shows that ginseng, hawthorn, pentadecanoic acid, and formulas 1-7 all have cholesterol-lowering effects, specifically by reducing the cholesterol fluorescence intensity of zebrafish tail blood vessels. The concentrations of the combined ingredients in the two- and three-component formulas are lower than those of the individual ingredients in the single-component formulas. Under these concentration differences, the cholesterol-lowering effects of the two- and three-component formulas are statistically significantly better than those of the single-component formulas: the cholesterol-lowering effects of the two-component combination of ginseng + pentadecanoic acid (1:5.5) and hawthorn + pentadecanoic acid (1:5.5) are both superior to those of the single-component formulas. The cholesterol-lowering effects of the three-component combination of ginseng + hawthorn + pentadecanoic acid (1:1:5.5, 1:0.1:10, 1:1:0.1, and 1:0.5:0.5) are all superior to those of the single-component formulas; among them, the cholesterol-lowering effect of (1:1:5.5) is superior to that of the two-component combination of ginseng + pentadecanoic acid (1:5.5) and hawthorn + pentadecanoic acid (1:5.5).

[0048] Table 1. Experimental results evaluating the cholesterol-lowering efficacy of the samples.

[0049]

[0050] Example 2 Evaluation of the efficacy in lowering triglycerides

[0051] 1. Experiment Content

[0052] Five dpf wild-type AB strain zebrafish were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker (experimental group). Samples were administered in water (sample formulations and concentrations for each group are shown in Table 2). Atorvastatin calcium was used as a positive control at a concentration of 11.6 μg / mL. A normal control group and a model control group were also included. Each beaker had a volume of 25 mL. Except for the normal control group, all experimental groups were given a high-fat diet in water to establish a zebrafish hyperlipidemia model. After treatment at 28℃ for 2 days, whole-body fat was stained with Oil Red O. After staining and bleaching, 10 zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The staining intensity (T) of the zebrafish tail vessels was analyzed, and the statistical analysis results of this index were used to evaluate the triglyceride-lowering efficacy of the samples. Statistical results are expressed as mean ± SE.

[0053] 2. Experimental Results

[0054] As shown in Table 2, Figure 2 As shown in Table 2, compared with the model control group, p < 0.001; Figure 2 Compared with the model control group, p < 0.001, compared with ginseng powder; &&& p < 0.001, compared with hawthorn powder. p < 0.001, compared with pentadecanoic acid, p < 0.001, compared with ginseng powder: pentadecanoic acid (1:5.5), p < 0.001, compared with hawthorn powder: pentadecanoic acid (1:5.5), p < 0.01.

[0055] Analysis of the above results shows that ginseng, hawthorn, pentadecanoic acid, and formulations 1-7 all have triglyceride-lowering effects. Specifically, they reduce the staining intensity of triglycerides in the blood vessels of zebrafish tails. The concentrations of the combined ingredients in the two and three formulations are lower than those of the individual ingredients in the single formulations. Under such concentration difference conditions, the triglyceride-lowering effects of the two and three formulations of this invention are statistically significantly better than those of the single formulations. The triglyceride-lowering effects of the two-formulation combinations of ginseng + hawthorn (1:1), ginseng + pentadecanoic acid (1:5.5), and hawthorn + pentadecanoic acid (1:5.5) are all superior to those of the single formulations. The triglyceride-lowering effects of the three-component combination of ginseng + hawthorn + pentadecanoic acid (1:1:5.5, 1:0.1:10, 1:1:0.1 and 1:0.5:0.5) are all superior to those of the single-component combination; the triglyceride-lowering effect of (1:1:5.5) is superior to that of the two-component combination of ginseng + hawthorn (1:1), ginseng + pentadecanoic acid (1:5.5) and hawthorn + pentadecanoic acid (1:5.5).

[0056] Table 2. Experimental results evaluating the triglyceride-lowering efficacy of the samples.

[0057]

[0058] The above embodiments illustrate and describe the main features and advantages of the present invention in detail. However, the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention. All such equivalent modifications or substitutions are included within the scope defined by the claims of the present invention.

Claims

1. A composition, characterized in that, The composition consists of 0.1-10 parts by weight of pentadecanoic acid and 1 part by weight of ginseng; Alternatively, the composition may consist of 0.1-10 parts by weight of pentadecanoic acid and 0.1-5 parts by weight of hawthorn; Alternatively, the composition may consist of 0.1-10 parts by weight of pentadecanoic acid, 1 part by weight of ginseng, and 0.1-5 parts by weight of hawthorn; The ginseng and hawthorn are ginseng powder and hawthorn powder prepared by water extraction, respectively.

2. The composition according to claim 1, characterized in that, The composition consists of 0.1-5.5 parts by weight of pentadecanoic acid and 1 part by weight of ginseng; Alternatively, the composition may consist of 0.1-5.5 parts by weight of pentadecanoic acid and 0.5-5 parts by weight of hawthorn; Alternatively, the composition may consist of 0.1-5.5 parts by weight of pentadecanoic acid, 1 part by weight of ginseng, and 0.5-5 parts by weight of hawthorn.

3. The composition according to claim 1, characterized in that, The composition consists of 0.1-5.5 parts by weight of pentadecanoic acid and 0.5-1 parts by weight of hawthorn; Alternatively, the composition may consist of 0.1-5.5 parts by weight of pentadecanoic acid, 1 part by weight of ginseng, and 0.5-1 part by weight of hawthorn.

4. The composition according to any one of claims 1-3, characterized in that, In the composition: The ginseng in question has a ginsenoside content of Rg1+Re≥0.9% and Rb1≥0.6%. The citric acid content of the hawthorn is ≥2.5%.

5. A food product comprising the composition according to any one of claims 1-4; The food product uses only the composition according to any one of claims 1-4 as an active ingredient that helps maintain healthy blood lipid levels.

6. The food product according to claim 5, characterized in that, The food products mentioned are nutritional products, health foods, or foods formulated for special medical purposes.

7. The food product according to claim 6, characterized in that, The food product is adult formulated milk powder.

8. The use of the composition according to any one of claims 1-4 or the food according to any one of claims 5-7 in the preparation of products that help maintain healthy blood lipid levels.

9. The application according to claim 8, characterized in that, The blood lipids include cholesterol and / or triglycerides.

10. The application according to claim 8, characterized in that, The product in question is a pharmaceutical or health food product.

Images